Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying
Cycle design and robustness testing using advanced process analytical technology.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 88-93

where ΔH s is the heat of sublimation of ice (670 cal/g used as constant), P ice is the vapor pressure of ice (Torr, known from the first experiment), P c is the chamber pressure (Torr), R p and Rs are the product and stopper resistance, respectively (cm2 Torr h/g, known from the first experiment), A v is the vial outer cross-sectional area (6.83 cm2), K v is the vial heat transfer coefficient (104 cal/sec cm2 K, cf.) (see Table I), T s is the shelf-inlet temperature (C) and Tb the temperature at the bottom of the vial (C).


Table I: Summary of process conditions for 50–200 mg/mL sucrose solutions and corresponding maximum product temperature data (Tp-max) during primary drying.
Table I illustrates the theoretical values obtained from the steady-state model for the maximum product temperature (T p-max ) when using a 5 C shelf temperature variation at constant pressure (62 mTorr) or an increase in chamber pressure from 62 to 200 mTorr at constant T s .


Figure 4
The modeled results obtained for T p-max were found in fairly good agreement to the experimental data. Note that this observation has been reported in the literature (11). However, the effect of T s and P c on product temperature was lower in the experiments performed relative to the theoretical calculations, in particular for applied pressure changes. Although such simulation is useful for scale-up, rational design of the freeze-drying process and troubleshooting, simulations cannot eliminate the need for careful experimentation (12).


Figure 5
Product resistance. Rp data determined for products dried by the optimized cycle increased almost linearly over Ldry, indicating an absence of shrinkage and microcollapse (see Figure 4) (4, 5). The variation of T s by 5C showed no clear impact on R p. However, the pressure increase up to 200 mTorr resulted in a significant decrease in R p over L dry. Microcollapse as well as shrinkage in these products could be detected visually and by SEM (see Figure 5b).

Note that an increase in solute concentration led to a similar R p curve shape relative to the samples at high P c, but the product matrix revealed much greater robustness to elevated temperature (see Figures 4 and 5c). This observation was in excellent agreement with the T c difference measured by FDM between 50 mg/mL (T c= –34 C) and 200 mg/mL (T c = –32 C) sucrose solutions. Note that the dependency of sucrose concentration on T c was recently investigated but is in contrast to data obtained in early studies on a different amorphous system (8, 13).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here